Advertisement

HRT, Plasma Risk Factors, and Cardiovascular Disease

  • Gerd Assmann
  • Paul Cullen
  • Helmut Schulte
Part of the Medical Science Symposia Series book series (MSSS, volume 11)

Abstract

Although the menopause, defined as the last menstrual bleeding due to exhaustion of the ovarian follicles, is a discrete event, events leading to the menopause, in particular the gradual reduction in ovarian function and decrease in production and circulation of sex steroids, form part of a gradual process taking place over several years. The mean age of females at the time of the last bleeding is 50–51 years. At current life expectancies, about a third of a woman’s life is after the menopause. Menopause is a physiological event, but the accompanying decrease in circulating estrogen often leads to nonphysiological symptoms such as hot flushes and an increased risk of cardiovascular disease as well as osteoporosis.

Keywords

Coronary Heart Disease Plasma Lipoprotein Estrogen Replacement Therapy Hepatic Lipase Postmenopausal Estrogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Statistisches Bundesamt, W. Statistisches Jahrbuch für die Bundesrepublik Deutschland 1995. Metzler-Poeschel Verlag, Stuttgart. 1995.Google Scholar
  2. 2.
    World Health Organisation. World Health Statistics Annual 1988. Geneva, WHO. 1988.Google Scholar
  3. 3.
    National Center for Health Statistics. 1993. Vital statistics of the United States, 1989. Mortality, Part A (DHHS publication no. (PHS) 93-1101). Government Printing Office, Washington D.C.Google Scholar
  4. 4.
    Higgins M, Thom T. Trends in CHD in the United States. Int J Epidemiol 1989;19:S58–S66.CrossRefGoogle Scholar
  5. 5.
    Eaker ED, Chesbro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. Cardiovascular disease in women. Circulation 1993;88:1999–2009.PubMedCrossRefGoogle Scholar
  6. 6.
    Cohn PF. 1988. Silent myocardial ischemia. Ann Intern Med 1988;109:312–17.PubMedGoogle Scholar
  7. 7.
    Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. New Engl J Med 1993;329:247–56.PubMedCrossRefGoogle Scholar
  8. 8.
    Matthews K A, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. New Engl J Med 1989;321:641–46.PubMedCrossRefGoogle Scholar
  9. 9.
    Razay G, Heaton KW, Bolton CH. Coronary heart disease risk factors in relation to menopause. Q J Med 1992;85:307–8.Google Scholar
  10. 10.
    Jensen J, Nilas L, Christiansen C. 1990. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990;12:321–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Stevenson JC, Crook D, Godsland IF. Effects of age and menopause on lipid metabolism in healthy women. Atherosclerosis 1993;98:83–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Assmann G, Schulte H, von Eckardstein A. 1996. Hypertriglyceridemia and elevated levels of lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Kannel WB, Vokonas PS. Demographics of the prevalence, incidence, and management of coronary heart in the elderly and in women. Ann Epidemiol 1992;2:5–14.PubMedCrossRefGoogle Scholar
  14. 14.
    Balfour JA, Hee RC. Transdermal oestradiol: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990:40:561–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Siiteri PK, Murai JT, Hammonds GL. 1982. The serum transport of steroid hormones. Recent Prog Horm Res 1982;38:457–510.PubMedGoogle Scholar
  16. 16.
    Tarn SP, Archer TK, Deeley RG. Effects of estrogen on apolipoprotein secretion by the human hepatocarcinoma cell line HepG2. J Biol Chem 1985;260:1670–75.Google Scholar
  17. 17.
    Teichmann AT. 1993. Pharmacology of female sex hormones with respect to lipid and lipoprotein metabolism. In: Steinmetz A, Schneider J, Kaffarnik H, editors. Hormones in lipoprotein metabolism. Springer: Heidelberg, 1993: 71–87.CrossRefGoogle Scholar
  18. 18.
    Henrikkson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels. J Clin Invest 1992;89:1166–71.CrossRefGoogle Scholar
  19. 19.
    Soma M, Fumagalli R, Paoletti R, et al. Plasma Lp(a) concentration after oestrogen and progestogen in postmenopausal women (letter). Lancet. 1991;337:612.PubMedCrossRefGoogle Scholar
  20. 20.
    Van der Mooren MJ, Demacker PNM, Thomas CMG, Rolland R. Beneficial effect on serum lipoproteins by 17-oestradiol-dydrogestrone therapy in postmenopausal women: A prospective study. Eur J Obstet Gynecol Reprod Biol 1992;47:153–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Marsh M S, Crook D, Ellerington MC, Whitcroft SI, Whitehead MI, Stevenson JC. Effect of continuous combined estrogen replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 1994;83:19–23.PubMedGoogle Scholar
  22. 22.
    Zechner R, Desoie G, Schweditsch MO, Pfeiffer KP, Kostner GM. Fluctuations of plasma lipoprotein(a) concentration during pregnancy and post parturition. Metabolism 1986;35:333–36.PubMedCrossRefGoogle Scholar
  23. 23.
    Seed M, Doherty E, O’Connor B, Reaveley D. Effect of high endogenous oestradiol on lipoprotein concentrations (abstract). J Endocrinol 1991;131(Suppl.):73.Google Scholar
  24. 24.
    Nikkila EA, Tikkanen M, Spinen S. Decrease of plasma high density lipoprotein (HDL) and increase of postheparin plasma hepatic lipase activity during progestin (levonorgestrel) treatment (abstract). Circulation 1980;62(Suppl.):228Google Scholar
  25. 25.
    Tikkanen MJ, Kuusi T, Sipinen S, Nikkila EA. Hepatic lipase and plasma HDL concentrations during progestogen treatment in women (abstract). Eur J Clin Invest 1980;10(Suppl.):37Google Scholar
  26. 26.
    Crook D. Postmenopausal oestrogens and progestogens: Effects on plasma lipoprotein risk markers for coronary heart disease. In: Asch R, Studd JWW, editors. Progress in reproductive medicine. Ithaca, NY: Parthenon, 1993:261–72.Google Scholar
  27. 27.
    Nabulis AA, Folsom AR, White A, et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069–75.CrossRefGoogle Scholar
  28. 28.
    Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New Engl J Med 1991;325:1196–1204.PubMedCrossRefGoogle Scholar
  29. 29.
    Seed M, Crook D. Post-menopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins. Curr Opin Lipidol 1994;5:48–58.PubMedCrossRefGoogle Scholar
  30. 30.
    Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. New Engl J Med 1986;314:1615–20.PubMedCrossRefGoogle Scholar
  31. 31.
    Pattison NS, Uptin T, Knox B, France J. Transdermal oestrogen for menopausal women: A double blind crossover comparative study with ethinyl oestradiol. Aust N Z J Obstet Gynaecol 1989;29:62–65.PubMedCrossRefGoogle Scholar
  32. 32.
    Crook D, Cust MP, Gangar KF, et al. 1992. Comparison of transdermal and oral oestrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;269:3015–23.Google Scholar
  33. 33.
    Gotto AM, Assmann G, Carmena R, Davignon J, Fernandez-Cruz A, Paoletti R. The ILIB lipid handbook for clinical practice. Blood lipids and coronary heart disease. International Lipid Information Bureau, Houston. 1995.Google Scholar
  34. 34.
    Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses’ Health Study. New Engl J Med 1991;325:756–62.PubMedCrossRefGoogle Scholar
  35. 35.
    Falkeborn M, Persson I, Adami H-O, et al. 1992. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obestet Gynaecol 1992;99:821–28.CrossRefGoogle Scholar
  36. 36.
    Stampfer MJ, Colditz GA. 1991. Estrogen replacement therapy and coronary heart disease: Quantitative assessment of the epidemiologic evidence. Prev Med 1991;273:47–63.CrossRefGoogle Scholar
  37. 37.
    Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37.PubMedGoogle Scholar
  38. 38.
    Collins P, Rosano GMC, Sarrel PM, et al. Beta-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Chen SJ, Li H, Durand J, Oparil S, Chen YF. 1996. Estrogen reduces myointimal proliferation after balloon injury or rat carotid artery. Circulation 1996;93:577–84.PubMedCrossRefGoogle Scholar
  40. 40.
    Miller VT, Larosa J, Barnabei V, et al. 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women — the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995;273:199–208.CrossRefGoogle Scholar
  41. 41.
    Kannel WB, Wilson PWF. 1995. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995;155:57–61.PubMedCrossRefGoogle Scholar
  42. 42.
    Goldschmid MG, Barrett-Connor E, Edelstein SL, Wingard DL, Cohn BA, Herman WH. Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. Circulation 1994;89:991–97.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1997

Authors and Affiliations

  • Gerd Assmann
  • Paul Cullen
  • Helmut Schulte

There are no affiliations available

Personalised recommendations